

AMOÉBA inaugurates its first industrial site in Lyon - Chassieu

Lyon, 03 October 2016 - AMOÉBA (FR0011051598 - AMEBA), producer of a biological biocide capable of eliminating waterborne bacterial risk, announces the inauguration of its industrial site based in Lyon-Chassieu.

In the direct follow-up to the industrial development activities carried out in partnership with the Toulouse White Biotechnology "TWB" excellence centre, AMOÉBA is today inaugurating its European production unit which includes two 500-litre bioreactors capable of producing up to 100m³ of BIOMEBA annually.

These bioreactors will continuously produce the amoeba *Williaertia magna* by a suspension culture method. This production method has been tested by AMOÉBA during the various phases of validation of its industrial process. The method represents true scientific progress. It notably contributes to simplifying the industrialisation process while also providing other advantages such as reducing direct costs of raw materials and optimising post-culture phases.



AMOÉBA intends to add further production lines based on the same type of 500-litre reactor as the need for its product, BIOMEBA, increases.

The production unit launched today will supply the European distribution network which AMOÉBA has developed through the signing of letters of intent as part of distribution agreements. The network will become active once provisional MA has been granted, which is expected to take place in the second half of 2016.

The first market targeted by AMOÉBA is that of ACT - (non-nuclear) industrial air cooled towers - a market which is estimated to be worth 1.7bn euro.

"We are delighted with the construction of this first fully operational production unit. The inauguration of our site in Chassieu is the culmination of a fruitful collaboration with Toulouse White Biotechnology and our scientific teams for the development of a unique production tool at the forefront of innovation." indicates **Fabrice PLASSON, President of AMOÉBA's Board of Directors**



About AMOEBA: Based in Chassieu - France, AMOEBA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.). This entirely natural solution is presented as an alternative to the chemical treatments traditionally used in the industrial sector and complies with the new regulations in terms of chemical emissions into the environment. In a worldwide market for chemical biocides estimated to be worth EUR 21 bn(1), AMOEBA is today concentrating on the segment of industrial air-cooled towers (ACT), estimated to be worth EUR 1.7 bn(2). AMOEBA is continuing with the regulatory procedures necessary to obtain provisional MA for all European countries for the "Air Cooled Towers" application. AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. For more information: www.amoeba-biocide.com.

(1) : Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets

(2) : Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

Contacts:

Amoéba
Lucile GAUTHIER
Head of Communication
+33 4 81 13 05 62
lucile.gauthier@amoeba-biocide.com

Actifin
Ghislaine GASPARETTO
Financial Communication
+33 1 56 88 11 11
ggasparetto@actifin.fr